Immunotherapy and Pancreatic Cancer: Unique Challenges and Potential Opportunities

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2018 Dec 22

PMID 30574212

Citations 39

Authors

Kate Young

Daniel J Hughes

David Cunningham

Naureen Starling

Affiliations

Soon will be listed here.

Abstract

Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over 300,000 deaths per year globally there is an urgent unmet need to improve the therapeutic options available. Novel immunotherapies have shown promising results across multiple solid tumours, in a number of cases surpassing chemotherapy as a first-line therapeutic option. However, to date, trials of single-agent immunotherapies in PDAC have been disappointing and PDAC has been labelled as a nonimmunogenic cancer. This lack of response may in part be attributed to PDAC's unique tumour microenvironment (TME), consisting of a dense fibrotic stroma and a scarcity of tumour infiltrating lymphocytes. However, as our understanding of the PDAC TME evolves, it is becoming apparent that the problem is not simply the immune system failing to recognize the cancer. There is a highly complex interplay between stromal signals, the immune system and tumour cells, at times possibly restraining tumour growth and at others supporting growth and metastasis. Understanding this complexity will enable the development of rational combinations with immunotherapy, priming the TME to offer immunotherapy the best chance of success. This review seeks to describe the unique challenges of the PDAC TME, the potential opportunities it may afford and the trials in progress capitalizing on recent insights in this area.

Citing Articles

Pembrolizumab followed by irreversible electroporation of a liver metastasis in pancreatic cancer patients.

Flak R, Kofod-Olsen E, Solvsten N, Naujokaite G, Agger R, Stender M iScience. 2024; 27(10):111026.

PMID: 39610376 PMC: 11602522. DOI: 10.1016/j.isci.2024.111026.

Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy.

Giurini E, Ralph O, Pappas S, Gupta K Mol Cancer Ther. 2024; 24(1):18-32.

PMID: 39311547 PMC: 11694065. DOI: 10.1158/1535-7163.MCT-24-0311.

Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study.

Amin S, Lin C Gastro Hep Adv. 2024; 3(3):302-310.

PMID: 39131143 PMC: 11307788. DOI: 10.1016/j.gastha.2023.12.004.

Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.

Cysneiros M, Cirqueira M, Barbosa L, Oliveira E, Morais L, Wastowski I PLoS One. 2024; 19(7):e0305648.

PMID: 38954689 PMC: 11218951. DOI: 10.1371/journal.pone.0305648.

Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.

Nakazawa Y, Miyano M, Tsukamoto S, Kogai H, Yamamoto A, Iso K Nat Commun. 2024; 15(1):2192.

PMID: 38467634 PMC: 10928091. DOI: 10.1038/s41467-024-46167-1.

References

von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C . Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001; 7(3 Suppl):925s-932s. View

Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz R . Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7(12):3862-8. View

Nakata B, Wang Y, Yashiro M, Nishioka N, Tanaka H, Ohira M . Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res. 2002; 8(8):2536-40. View

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T . CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004; 28(1):e26-31. DOI: 10.1097/00006676-200401000-00023. View

Li D, Xie K, Wolff R, Abbruzzese J . Pancreatic cancer. Lancet. 2004; 363(9414):1049-57. DOI: 10.1016/S0140-6736(04)15841-8. View

Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N . Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004; 95(7):583-7. PMC: 11158491. DOI: 10.1111/j.1349-7006.2004.tb02490.x. View

Qu C, Li Y, Song Y, Rizvi S, Raja C, Zhang D . MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer. 2004; 91(12):2086-93. PMC: 2409789. DOI: 10.1038/sj.bjc.6602232. View

Maple J, Smyrk T, Boardman L, Johnson R, Thibodeau S, Chari S . Defective DNA mismatch repair in long-term (> or =3 years) survivors with pancreatic cancer. Pancreatology. 2005; 5(2-3):220-7. DOI: 10.1159/000085275. View

Furuyama K, Doi R, Mori T, Toyoda E, Ito D, Kami K . Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg. 2006; 30(2):219-26. DOI: 10.1007/s00268-005-0165-z. View

10.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S . Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006; 12(18):5423-34. DOI: 10.1158/1078-0432.CCR-06-0369. View

11.

Kleeff J, Beckhove P, Esposito I, Herzig S, Huber P, Lohr J . Pancreatic cancer microenvironment. Int J Cancer. 2007; 121(4):699-705. DOI: 10.1002/ijc.22871. View

12.

Clark C, Hingorani S, Mick R, Combs C, Tuveson D, Vonderheide R . Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67(19):9518-27. DOI: 10.1158/0008-5472.CAN-07-0175. View

13.

Hwang R, Moore T, Arumugam T, Ramachandran V, Amos K, Rivera A . Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008; 68(3):918-26. PMC: 2519173. DOI: 10.1158/0008-5472.CAN-07-5714. View

14.

Chatzizacharias N, Kouraklis G, Theocharis S . Clinical significance of FAK expression in human neoplasia. Histol Histopathol. 2008; 23(5):629-50. DOI: 10.14670/HH-23.629. View

15.

Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B . Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008; 14(5):1455-63. PMC: 2879140. DOI: 10.1158/1078-0432.CCR-07-0371. View

16.

Hermann P, Huber S, Herrler T, Aicher A, Ellwart J, Guba M . Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2008; 1(3):313-23. DOI: 10.1016/j.stem.2007.06.002. View

17.

Kondo H, Hazama S, Kawaoka T, Yoshino S, Yoshida S, Tokuno K . Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res. 2008; 28(1B):379-87. View

18.

Witkiewicz A, Williams T, Cozzitorto J, Durkan B, Showalter S, Yeo C . Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg. 2008; 206(5):849-54. DOI: 10.1016/j.jamcollsurg.2007.12.014. View

19.

Haynes N, van der Most R, Lake R, Smyth M . Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol. 2008; 20(5):545-57. DOI: 10.1016/j.coi.2008.05.008. View

20.

Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, Yahara N . Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep. 2008; 20(1):155-63. View